Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Administration of Recombinant Human Serum Albumin/Erythropoietin Fusion Protein for Injection, Tolerance, Safety, Pharmacokinetics and Pharmacodynamic Clinical Trials of Increased Dosage

NCT03786289 is registered in ClinicalTrials.gov with Tianjin SinoBiotech Ltd. as lead sponsor.

NCT NCT03786289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03786289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Administration of Recombinant Human Serum Albumin/Erythropoietin Fusion Protein for Injection, Tolerance, Safety, Pharmacokinetics and Pharmacodynamic Clinical Trials of Increased Dosage
Lead sponsor
Tianjin SinoBiotech Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 3, 2018
Completion date
December 9, 2019
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects